Cosmos Health (COSM) said late Thursday it has signed a non-binding letter of intent to acquire Doc Pharma, a fully licensed GMP pharmaceutical manufacturer.
The proposed acquisition is part of its plan to build an end-to-end healthcare platform, the company said.
Doc Pharma has an asset base of about $24 million and generated some $6.7 million in three-year average annual revenue, it added.
Price: $0.21, Change: $-0.02, Percent Change: -10.00%